Researchers from the Critical Analytics for Manufacturing Personalized-Medicine (CAMP) interdisciplinary research group at ...

Allows for the processing of allogeneic (non-autologous) donor tissue material, including stem cells, for medical research – MELVILLE, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- . (“BioRestorative”, ...

Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline results ...

For the quarter ended September 30, 2024, the Company had a loss from operations of $2.3 million, a 26% year-over-year improvement from $3.1 million for the comparable period of 2023, and a 9% ...

Researchers have developed a novel method to enhance the ability of mesenchymal stromal cells ... the yield and quality of cell therapy products could be significantly increased.

By controlling metabolic conditions such as AA supplementation, coupled with CAMP’s process analytical tools such as µMRR, the yield and quality of cell therapy products could be significantly ...

Aegle Therapeutics says that its mission is to harness the regenerative, immunomodulatory, and anti-inflammatory potential of ...

New blinded preliminary safety and efficacy data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in podium presentation on ...

Stem cells grown in microgravity aboard the International Space Station (ISS) are showing potential to transform treatments ...